Last reviewed · How we verify
Empagliflozin 10 milligram
Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.
At a glance
| Generic name | Empagliflozin 10 milligram |
|---|---|
| Also known as | Jardiance |
| Sponsor | Ain Shams University |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, empagliflozin allows glucose to be excreted in the urine rather than reabsorbed into the bloodstream, thereby lowering blood glucose levels. This mechanism is independent of insulin secretion or action, making it effective across different stages of type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Polydipsia
- Diabetic ketoacidosis
- Volume depletion